Clinical trials: Over Cancer
Melanoma (Skin)
PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma
RATIONALE: Peginterferon (PEG-interferon) alfa-2b may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of PEG-interferon alfa-2b in treating patients who have stage…
- Trial name
- NCT00049530
- Testing
- PEG-interferon alfa-2b
- Where
- 32 sites in United States
- Volunteers
- 32 people
- Sponsor
- Eastern Cooperative Oncology Group
Malodorous Infected Cutaneous Ulcer
An Open, Uncontrolled Study of GK567 in the Deodorization of Malodorous Fungating Neoplastic Tumours
This clinical trial objective is to investigate the safety and efficacy of GK567 to alleviate malodour of foul smelling, anaerobically infected fungating neoplastic tumours, over 14 days of treatment.
- Trial name
- GK567 (NCT01541930)
- Testing
- GK567
- Where
- 2 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Galderma R&D
Solid Tumors, Lymphoma
A Phase I Study of Zalypsis (PM00104) in Subjects With Advanced Malignant Solid Tumors or Lymphoma
Phase I trial, dose escalating, prospective, open-label, non-randomized, multicenter study. The purpose is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended dose (RD) of PM00104, administered…
- Trial name
- NCT00359294
- Testing
- PM00104
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- PharmaMar
Multiple Myeloma
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
To explore whether Elotuzumab dose administration over approximately 60 minutes is feasible and safe.
- Trial name
- NCT02159365
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 29 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Non-small Cell Lung Cancer
A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC.
- Trial name
- NCT05171777
- Testing
- Atezolizumab
- Where
- 36 sites in United States, Argentina and 10 more
- Volunteers
- 179 people
- Sponsor
- Hoffmann-La Roche
Neoplasms, Breast
ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
This study was originally designed as a Phase III randomized, double blind, placebo controlled study to assess the safety and tolerability, and efficacy of paclitaxel plus trastuzumab plus lapatinib compared with paclitaxel plus…
- Trial name
- NCT00272987
- Testing
- lapatinib, paclitaxel, trastuzumab
- Where
- 16 sites in United States, Belgium
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a…
- Trial name
- METRIC (NCT01997333)
- Testing
- CDX-011, Capecitabine
- Where
- 140 sites in United States, Australia and 7 more
- Volunteers
- 327 people
- Sponsor
- Celldex Therapeutics
Asthma
Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
Study to assess the efficacy and safety of four doses of budesonide inhalation aerosol (BD MDI, PT008) relative to placebo MDI in adult subjects with mild to moderate persistent asthma.
- Trial name
- NCT02105012
- Testing
- BD MDI 320 µg, BD MDI 160 µg, BD MDI 80 µg
- Where
- 41 sites in United States
- Volunteers
- 147 people
- Sponsor
- Pearl Therapeutics, Inc.
Cancer, With Caregiver Support Time
French Validation of an Interview Guide to Cancer Announcement : the Psycho Oncology Basic Documentation
Validation of the PO-BADO in its short and long versions that need a standardized validation process with the inclusion of 450 Patients
- Conditions
- Cancer, With Caregiver Support Time, 18 Years and Over
- Trial name
- PO-BADO (NCT02874001)
- Volunteers
- 252 people
- Sponsor
- Institut Bergonié
Head and Neck Neoplasms, Carcinoma, Squamous Cell
BIBW 2992 (Afatinib) in Head & Neck Cancer
The primary objective of this study is to explore the efficacy of BIBW 2992 compared with cetuximab (Erbitux) in patients with metastatic or recurrent head and neck cancer after failure of platinum-containing therapy.
- Trial name
- NCT00514943
- Testing
- BIBW 2992, Cetuximab
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 124 people
- Sponsor
- Boehringer Ingelheim
Kidney Failure, Chronic
Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands
This observational study will evaluate the clinical benefit of Zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands.
- Trial name
- NCT01273597
- Where
- 11 sites in Hungary
- Volunteers
- 60 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Progressive Desmoids Tumors
PAZOPANIB Efficacy and Tolerance in Desmoids Tumors
Desmoids tumors are benign soft tissues tumors characterized by aggressiveness and potential local recurrence. There is a female predominance with a sex ratio of 2/1 and median age at diagnosis is about 30 years.
- Trial name
- DESMOPAZ (NCT01876082)
- Testing
- PAZOPANIB treatment, Active Comparator: Vinblastine and Methotrexate
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Institut Bergonié
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Acute Myeloid Leukemia
Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65
The purpose of this study is to find out if by giving a combination of 3 drugs the leukemia will go into complete remission (meaning the leukemia is completely gone), and to find out how long it stays away.
- Trial name
- EXJADE (NCT02341495)
- Testing
- Deferasirox, Cholecalciferol, Azacitidine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Elizabeth Henry
Breast Cancer
Use of Cognitive Stimulation Software for Patients Over the Age of 70 Followed for Breast Cancer: COG-TAB-AGE Feasibility Study
Numerous studies have shown the impact of anti-cancer treatments on cognition and more particularly that of chemotherapy. Elderly patients also seem to be at higher risk of developing cognitive impairment.
- Trial name
- COG-TAB-AGE (NCT04261153)
- Testing
- Cognitive stimulation
- Where
- 2 sites in France
- Volunteers
- 55 people
- Sponsor
- Centre Francois Baclesse
Alopecia Areata
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks.
- Trial name
- NCT02974868
- Testing
- PF-06651600, PF-06700841
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 142 people
- Sponsor
- Pfizer
Breast Cancer
External-Beam Partial-Breast Irradiation for Early Breast Cancer 40 Gy QD Over 2 Weeks
Standard therapy for patients with early stage breast cancer consists of surgery to remove the cancer followed by radiation therapy.
- Trial name
- NCT01581619
- Testing
- External Beam Partial-Breast Irradiation
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Massachusetts General Hospital
Lymphoid Malignancies
Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820
The primary objective of this study is to provide idelalisib to participants receiving GS-9820 in Gilead-sponsored Study GS-US-315-0102 at the time of study closure.
- Trial name
- NCT02739360
- Testing
- Idelalisib
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- Gilead Sciences
Neurofibroma, Plexiform, Neurofibromatosis Type I
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
This study will examine whether the experimental drug R115777 (Tipifarnib) can shrink or slow the growth of plexiform neurofibromas in children and young adults with neurofibromatosis type 1 (NF1) and determine what side effects…
- Trial name
- NCT00021541
- Testing
- tipifarnib
- Where
- 12 sites in United States, Germany
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)